TD Cowen Reiterates “Buy” Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reiterated by TD Cowen in a research report issued on Thursday,Benzinga reports.

Several other brokerages have also recently issued reports on KURA. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Thursday. UBS Group started coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective for the company. Jefferies Financial Group dropped their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, HC Wainwright boosted their price target on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $29.38.

Kura Oncology Price Performance

Shares of KURA stock opened at $10.80 on Thursday. Kura Oncology has a twelve month low of $9.06 and a twelve month high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a fifty day simple moving average of $18.08 and a two-hundred day simple moving average of $19.76. The stock has a market capitalization of $839.85 million, a price-to-earnings ratio of -4.66 and a beta of 0.86.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in Kura Oncology in the first quarter worth about $110,000. ProShare Advisors LLC raised its position in shares of Kura Oncology by 9.7% in the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after purchasing an additional 1,588 shares during the last quarter. Vanguard Group Inc. boosted its stake in Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares in the last quarter. Avoro Capital Advisors LLC grew its position in Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after purchasing an additional 870,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Kura Oncology by 17.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after purchasing an additional 2,940 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.